Hyperuricemia as a prognostic factor after acute coronary syndrome

Area of Science:

• Cardiology
• Clinical Biochemistry

Background:

• Uric acid's link to cardiovascular disease is known, but its predictive role in acute coronary syndrome (ACS) outcomes is debated.
• Hyperuricemia's impact on medium/long-term prognosis post-ACS requires further clarification.

Purpose of the Study:

• To evaluate the association between hyperuricemia and clinical outcomes in ACS patients.
• To determine if incorporating hyperuricemia into the GRACE score enhances its predictive ability for ACS patients.

Main Methods:

• A cohort study of 1119 patients admitted for ACS (2008-2013) with a mean follow-up of 36 months.
• Multivariate analysis assessed associations with cardiovascular/total mortality and major adverse cardiovascular events (MACE).
• GRACE score reclassification and net reclassification improvement (NRI) were calculated after adding hyperuricemia.

Main Results:

• Hyperuricemia independently predicted higher cardiovascular mortality (HR 1.91), all-cause mortality (HR 1.59), and MACE (HR 1.36).
• Adding hyperuricemia to the GRACE score reclassified 26% of patients with a significant NRI of 34%.
• However, the increase in the area under the curve (AUC) was marginal (0.009) and not statistically significant.

Conclusions:

• Hyperuricemia is linked to adverse medium/long-term outcomes in ACS patients.
• While hyperuricemia improves risk stratification when added to the GRACE score, it does not significantly enhance predictive discrimination.
• Hyperuricemic patients in medium/high-risk categories faced elevated all-cause mortality.